Syndax Pharmaceuticals Inc (SNDX) 20 Days SMA touches -5.52%: The odds favor the bear

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) kicked off on Tuesday, down -7.11% from the previous trading day, before settling in for the closing price of $15.48. Over the past 52 weeks, SNDX has traded in a range of $12.06-$25.16.

During the last 5-year period, the sales growth of Healthcare Sector giant was 1801.91%. While this was happening, its average annual earnings per share was recorded -3.62%. With a float of $83.50 million, this company’s outstanding shares have now reached $85.69 million.

Let’s determine the extent of company efficiency that accounts for 270 employees. In terms of profitability, gross margin is -169.78%, operating margin of -1942.5%, and the pretax margin is -1796.46%.

Syndax Pharmaceuticals Inc (SNDX) Insider Activity

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Syndax Pharmaceuticals Inc is 2.18%, while institutional ownership is 117.69%. The most recent insider transaction that took place on Mar 04 ’25, was worth 214,986. Before that another transaction happened on Feb 10 ’25, when Company’s Chief Financial Officer sold 3,777 for $15.50, making the entire transaction worth $58,559. This insider now owns 90,746 shares in total.

Syndax Pharmaceuticals Inc (SNDX) Earnings and Forecasts

Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around -3.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 27.80% during the next five years compared to -15.16% drop over the previous five years of trading.

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Trading Performance Indicators

Take a look at Syndax Pharmaceuticals Inc’s (SNDX) current performance indicators. Last quarter, stock had a quick ratio of 5.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 51.83.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.73, a number that is poised to hit -1.24 in the next quarter and is forecasted to reach -2.80 in one year’s time.

Technical Analysis of Syndax Pharmaceuticals Inc (SNDX)

Looking closely at Syndax Pharmaceuticals Inc (NASDAQ: SNDX), its last 5-days average volume was 2.57 million, which is a jump from its year-to-date volume of 2.33 million. As of the previous 9 days, the stock’s Stochastic %D was 31.75%. Additionally, its Average True Range was 0.92.

During the past 100 days, Syndax Pharmaceuticals Inc’s (SNDX) raw stochastic average was set at 22.22%, which indicates a significant increase from 10.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 56.12% in the past 14 days, which was lower than the 66.05% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $14.21, while its 200-day Moving Average is $18.15. However, in the short run, Syndax Pharmaceuticals Inc’s stock first resistance to watch stands at $15.50. Second resistance stands at $16.63. The third major resistance level sits at $17.33. If the price goes on to break the first support level at $13.67, it is likely to go to the next support level at $12.97. Should the price break the second support level, the third support level stands at $11.84.

Syndax Pharmaceuticals Inc (NASDAQ: SNDX) Key Stats

The company with the Market Capitalisation of 1.23 billion has total of 85,358K Shares Outstanding. Its annual sales at the moment are 23,680 K in contrast with the sum of -209,360 K annual income. Company’s last quarter sales were recorded 12,500 K and last quarter income was -84,130 K.